Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $129,052.56 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Pascal Deschatelets sold 5,928 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $129,052.56. Following the completion of the transaction, the insider directly owned 1,151,382 shares in the company, valued at $25,065,586.14. This trade represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pascal Deschatelets also recently made the following trade(s):

• On Tuesday, January 20th, Pascal Deschatelets sold 909 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $19.79, for a total value of $17,989.11.
• On Tuesday, January 13th, Pascal Deschatelets sold 2,277 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $22.19, for a total value of $50,526.63.

Apellis Pharmaceuticals Stock Down 1.1%

Shares of NASDAQ:APLS opened at $21.76 on Monday. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $30.91. The stock has a market cap of $2.75 billion, a P/E ratio of 70.18 and a beta of 0.31. The business has a fifty day moving average of $23.02 and a two-hundred day moving average of $23.59. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Thursday, October 30th. The company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million for the quarter, compared to analyst estimates of $364.58 million. During the same quarter in the previous year, the firm earned ($0.46) EPS. The company’s quarterly revenue was up 133.0% compared to the same quarter last year. On average, research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of APLS. Simplify Asset Management Inc. acquired a new position in Apellis Pharmaceuticals in the 3rd quarter valued at about $2,419,000. Corton Capital Inc. purchased a new position in shares of Apellis Pharmaceuticals in the second quarter valued at approximately $364,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Apellis Pharmaceuticals by 43.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock valued at $1,838,000 after purchasing an additional 30,507 shares during the period. Highland Capital Management LLC acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at approximately $1,135,000. Finally, Schroder Investment Management Group increased its stake in Apellis Pharmaceuticals by 91.9% during the 2nd quarter. Schroder Investment Management Group now owns 485,615 shares of the company’s stock worth $8,406,000 after buying an additional 232,506 shares during the period. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Citigroup reduced their price target on shares of Apellis Pharmaceuticals from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Wall Street Zen upgraded Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. Bank of America raised Apellis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus reduced their price objective on shares of Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Twelve equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $33.53.

Apellis Pharmaceuticals News Summary

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: BofA upgraded APLS to Buy and cited a stronger-than-expected launch trajectory for Apellis’s newly approved kidney-disease therapy, assigning a $28 price target — a vote of confidence that implies material upside if commercial momentum continues. Apellis Raised to Buy at Bank of America
• Positive Sentiment: An analyst note highlights early uptake of Empaveli and argues current valuation understates its revenue potential; continued strong launch metrics could drive a re‑rating and support upside from current levels. Apellis Valuation Ignores Empaveli Potential, Says Analyst
• Neutral Sentiment: Wells Fargo trimmed its price target (from $29 to $26) but kept an Overweight rating — a mixed signal that reduces upside expectations while leaving institutional support intact. Wells Fargo lowers price target on Apellis
• Neutral Sentiment: RBC Capital reiterated a Hold rating, a neutral stance that may temper buying interest from investors seeking stronger analyst conviction. RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)
• Negative Sentiment: Multiple senior insiders — including CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others — filed Form 4 sales on Jan. 20–22 (large, clustered disposals totaling many tens of thousands of shares). Even if routine (diversification or option-related), clustered executive selling typically weighs on near‑term sentiment and likely contributed to the stock decline. See CEO filing for details. CEO Cedric Francois Form 4

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.